One Year Outcomes Among Children Identified With Celiac Disease Through A Mass Screening Program.
celiac disease
outcomes
screening
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
received:
16
11
2023
revised:
02
03
2024
accepted:
11
03
2024
medline:
15
4
2024
pubmed:
15
4
2024
entrez:
14
4
2024
Statut:
aheadofprint
Résumé
Celiac disease (CD) mass screening remains controversial in part because of a paucity of data to support its benefit. The Autoimmunity Screening for Kids (ASK) study is a mass screening study for pediatric CD and type 1 diabetes in Colorado. This study prospectively follows children ages 1-17 years who screened positive for tissue transglutaminase IgA autoantibodies (tTGA) in the ASK study subsequently referred for diagnostic evaluation. Children diagnosed with CD by biopsy or serologic criteria were included in this study. Evaluation at baseline and 12 month follow up included demographics, laboratory studies, symptoms, health-related quality of life (HRQoL), anxiety/depression, and gluten-free diet (GFD) adherence. Paired student-t, chi-square, and Wilcoxon sign rank tests compared baseline and follow up data. For symptom scores, odds of improvement were assessed. Of the 52 children with CD enrolled, 42 children completed 12-month follow up. On the symptom questionnaire completed at diagnostic evaluation, 38/42 children reported one or more symptoms. CD mean symptom severity and frequency scores improved from baseline to follow up (p <0.001). Reported HRQoL scores improved among caregivers (p=0.002). There was no significant change in reported anxiety or depression. Iron deficiency without anemia was common at baseline (21/24 children, 87.5%) and normalized at follow up (11/21 children, 52.3%). 26/28 families reported good or excellent GFD adherence. This novel study of children with CD identified through a mass screening program demonstrated improvement in symptoms, quality of life, and iron deficiency after one year follow up. This demonstrates that there may be benefit to CD mass screening.
Sections du résumé
BACKGROUND
BACKGROUND
Celiac disease (CD) mass screening remains controversial in part because of a paucity of data to support its benefit. The Autoimmunity Screening for Kids (ASK) study is a mass screening study for pediatric CD and type 1 diabetes in Colorado.
METHODS
METHODS
This study prospectively follows children ages 1-17 years who screened positive for tissue transglutaminase IgA autoantibodies (tTGA) in the ASK study subsequently referred for diagnostic evaluation. Children diagnosed with CD by biopsy or serologic criteria were included in this study. Evaluation at baseline and 12 month follow up included demographics, laboratory studies, symptoms, health-related quality of life (HRQoL), anxiety/depression, and gluten-free diet (GFD) adherence. Paired student-t, chi-square, and Wilcoxon sign rank tests compared baseline and follow up data. For symptom scores, odds of improvement were assessed.
RESULTS
RESULTS
Of the 52 children with CD enrolled, 42 children completed 12-month follow up. On the symptom questionnaire completed at diagnostic evaluation, 38/42 children reported one or more symptoms. CD mean symptom severity and frequency scores improved from baseline to follow up (p <0.001). Reported HRQoL scores improved among caregivers (p=0.002). There was no significant change in reported anxiety or depression. Iron deficiency without anemia was common at baseline (21/24 children, 87.5%) and normalized at follow up (11/21 children, 52.3%). 26/28 families reported good or excellent GFD adherence.
CONCLUSIONS
CONCLUSIONS
This novel study of children with CD identified through a mass screening program demonstrated improvement in symptoms, quality of life, and iron deficiency after one year follow up. This demonstrates that there may be benefit to CD mass screening.
Identifiants
pubmed: 38615728
pii: S1542-3565(24)00352-5
doi: 10.1016/j.cgh.2024.03.030
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.